Press release

Press release

November 23, 2017

Follicum receives patent approval in China

Follicum AB (“Follicum”) today announces that the Chinese Patent Office (SIPO) has granted the company’s patent application for stimulation of hair growth. Thanks to SIPO’s grant of patent number ZL 201280049850.X, Follicum has protection in China until 2032. The patent protects the company’s peptides in general and for the stimulation of hair growth specifically. CEO […]

November 20, 2017

Follicum applies for the start of a Phase II study at the German Medicines Agency

Follicum AB (“Follicum” or “the company”) today announced that the company has filed an application for the initiation of a Phase IIa clinical trial with FOL-005 on scalp to study hair growth to the German Medicines Agency, BfArM and to the Ethics Committees. The goal is to start the study after approval by the authorities […]

November 9, 2017

Follicum expands its collaboration with two prominent hair clinics for the implementation of the next Phase IIa study with FOL-005

Follicum AB (“Follicum”) recently made a preferential share issue which provided the company with SEK 23.5 million before costs. The liquidity paid to the company is partly intended to finance a Phase IIa clinical trial with the company’s drug candidate FOL-005. Follicum hereby announces that the company has chosen to work with the Clinical Research […]

September 11, 2017

Follicum’s diabetes project receives a grant from the Novo Nordisk Foundation

Follicum AB (“Follicum”) today announces that Professor Jan Nilsson´s research group at the Clinical Research Center, Lund University has been granted 400 000 Danish crowns from the Novo Nordisk Foundation to carry out pre-clinical diabetes studies with Follicum’s peptides. The aim of the pre-clinical experiments is to study the effects and mechanisms of action of […]

September 4, 2017

Follicum recruits a Chief Business Officer

Follicum AB (“Follicum”) today announces the recruitment of Gunnar Gårdemyr as its Chief Business Officer (“CBO”). Gårdemyr has 35 years of international experience which includes leadership, business development, global marketing and commercial strategy from the pharmaceutical and biotechnology industries. His most recent position was as CEO of Targovax AS in Norway. Prior to this he […]

August 2, 2017

Follicum successfully completes its Phase I / IIa clinical study of FOL-005 and prepares for a Phase II clinical study

Follicum AB (“Follicum”) has now obtained the final results from the completed phase I / IIa clinical study. The results after a three-month follow-up period following the completion of treatment with FOL-005, demonstrate that the rate of hair growth does return to its original level. The results thereby confirm that Follicum’s drug candidate FOL-005 stimulates […]

April 18, 2017

Follicum’s Clinical Study Shows Stimulation of Hair Growth

Follicum AB hereby announces that the FOL-005 study at the Charité hospital in Berlin, Germany, has shown a stimulation of hair growth in treatment of healthy volunteers. In February 2017, Follicum is able to announce that the company’s phase I/IIa clinical study of the FOL-005 candidate drug showed a good safety profile, and that no […]

April 5, 2017

Notice of Annual General Meeting

The shareholders of Follicum AB (publ), 556851-4532, are invited to the Annual General Meeting,  on Wednesday the 26 April 2017 at 16.00 (4.00 p.m.) (CEST), at Scheelevägen 22, Lund. Full invitation and agenda of the AGM in Swedish For further information, please contact: Jan Alenfall, CEO Phone: +46 (0) 46 19 21 97 E-mail: